Citadel Advisors
OVID icon

Citadel Advisors’s Ovid Therapeutics OVID Stock Holding History

Citadel Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.2K Sell
22,600
-84,300
-79% -$151K ﹤0.01% 12405
2025
Q4 		$174K Buy
106,900
+28,400
+36% +$43.7K ﹤0.01% 11159
2025
Q3 		$102K Buy
78,500
+62,900
+403% +$54.5K ﹤0.01% 11842
2025
Q2 		$5.15K Buy
15,600
+13,900
+818% +$4.19K ﹤0.01% 12230
2025
Q1 		$530 Sell
1,700
-700
-29% -$430 ﹤0.01% 14251
2024
Q4 		$2.24K Sell
2,400
-35,000
-94% -$39.2K ﹤0.01% 14103
2024
Q3 		$44.1K Buy
37,400
+27,100
+263% +$28.3K ﹤0.01% 12048
2024
Q2 		$7.92K Buy
10,300
+4,400
+75% +$12.2K ﹤0.01% 13221
2024
Q1 		$18K Buy
5,900
+3,700
+168% +$12.4K ﹤0.01% 13080
2023
Q4 		$7.08K Buy
+2,200
New +$7.52K ﹤0.01% 13313
2023
Q3 		– Sell
-9,600
Closed -$31.5K – 14867
2023
Q2 		$31.5K Sell
9,600
-1,400
-13% -$4.75K ﹤0.01% 12299
2023
Q1 		$28.4K Buy
11,000
+1,800
+20% +$4.26K ﹤0.01% 12788
2022
Q4 		$17.1K Sell
9,200
-14,000
-60% -$23.9K ﹤0.01% 13263
2022
Q3 		$43K Sell
23,200
-800
-3% -$1.67K ﹤0.01% 11733
2022
Q2 		$52K Sell
24,000
-6,700
-22% -$16.2K ﹤0.01% 11919
2022
Q1 		$96K Sell
30,700
-19,300
-39% -$60.7K ﹤0.01% 12327
2021
Q4 		$161K Buy
50,000
+19,400
+63% +$66.5K ﹤0.01% 12177
2021
Q3 		$103K Sell
30,600
-57,200
-65% -$209K ﹤0.01% 12831
2021
Q2 		$343K Buy
87,800
+25,200
+40% +$99.5K ﹤0.01% 10941
2021
Q1 		$252K Buy
62,600
+38,200
+157% +$127K ﹤0.01% 11213
2020
Q4 		$56K Sell
24,400
-31,200
-56% -$145K ﹤0.01% 10529
2020
Q3 		$319K Buy
55,600
+44,400
+396% +$297K ﹤0.01% 8030
2020
Q2 		$83K Buy
+11,200
New +$52.4K ﹤0.01% 9090

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Citadel Advisors's OVID Position: Q1 2026 in Review

Citadel Advisors reduced its Ovid Therapeutics (OVID) stake by 54% in Q1 2026, selling an estimated $769K and leaving 367,902 shares worth $817K. The position accounts for ﹤0.01% of the portfolio, ranked #8136.

Citadel Advisors first reported a position in OVID in Q2 2017 and has held it in 21 quarters since. The position peaked at $1.3M in Q4 2025. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Citadel Advisors held 367,902 shares of Ovid Therapeutics worth $817K as of Q1 2026.
  • Citadel Advisors sold 429,922 Ovid Therapeutics shares in Q1 2026, an estimated $769K.
  • Ovid Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8136 holding.
  • Citadel Advisors first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 21 quarters since.
  • Citadel Advisors's Ovid Therapeutics position peaked at $1.3M in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.